Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled ...
Zacks Investment Research on MSN
DXCM upgrades Stelo with AI-powered smart meal logging features
Dexcom DXCM recently announced an upcoming nationwide rollout of an AI-driven upgrade to its Stelo platform aimed at ...
ŌURA has signalled an entry into the consumer diabetes space, offering a new glucose feature for its ring that uses insights from Dexcom’s over-the-counter (OTC) continuous glucose monitor (CGM) Stelo ...
Four years ago, my life changed after a heart attack at the age of 33. While a quick coronary angioplasty meant my heart was mostly fine, the tests conducted at the same time revealed a bigger chronic ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...
After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. The device is now available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results